Company Overview and News

 
Malaysia on the verge of Internet revolution

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): Malaysia is in the cusp of its own Internet revolution, touching the lives of millions of Internet users on how they communicate daily from their homes and offices, while giving a big boost to e-commerce.
5031

 
Analyst reports

2018-10-08 thestar.com.my
THE acquisition of 44.5% SAP Express (SAP) shares by GDEX is projected to be positive in the long run as it enables the group to tap faster into the Indonesian express delivery landscape.
5031 5983

 
KLCI falls 0.57% as China calls off trade talks with US

2018-09-24 theedgemarkets
KUALA LUMPUR (Sept 24): The FBM KLCI fell 0.57% at the midday breakin line with the tumble at most regional markets after China called off the trade talks with US officials.
APEXF 7090 UPBMF 5031 5202 2089 9334 6033 7123 5199 KLKBY 2445 PNADF 5347 3026 3867 0026 TNABY 5819 2836 1902 TNABF HIPEF PNAGF

 
KLCI tracks region and ticks up but gains seen capped

2018-09-19 theedgemarkets
KUALA LUMPUR (Sept 19): The FBM KLCI ticked up in early trade this morning, tracking regional markets and lifted by select index-linked blue chips.
HLFBF 4588 PNADF 1082 5031 BATS 4162 2836 PNAGF 6033

 
Bursa shares turn lower at mid-morning

2018-08-06 malaymail
KUALA LUMPUR, Aug 6 — Share prices on Bursa Malaysia turned lower at mid-morning today on mild selling in selected heavyweights led by Digi and Dialog Group.
0143 3301 8869 UPBMF 5031 BSMAF 2089 7277 1818

2
KLCI takes a breather, stays unperturbed by Khazanah offers to resign

2018-07-26 theedgemarkets
KUALA LUMPUR (July 26): The FBM KLCI appeared to take a breather from its recent uptrend today, but not entirely perturbed by news of the offer by the entire Khazanah Nasional Bhd board to resign this morning.
HLFBF 9385 FB 1082 7113 5681 TPGVF 5031 BATS 4162 5246 9334 6033 TGLVY 5139 PNADF 5347 3301 0900 TNABY TNABF PNAGF 3719

 
Mixed reaction from investors of Khazanah-linked counters

2018-07-26 theedgemarkets
KUALA LUMPUR(July 26): There was a mixed reaction from investors of Khazanah Nasional Bhd-linked counters this morning, with some counters gaining and others the exact opposite, as news reports emerged that the board of directors of the Malaysian government’s strategic investment fund, including its managing director Tan Sri Azman Mokhtar, have offered to resign.
5031 5014 CIMDF 1023 4863 5347 5225 TNABY 6888 MYPRY AXXTF MYTEF TNABF Q0F IHHHF

 
Telekom Malaysia, Axiata lift KLCI despite shaky regional markets

2018-07-04 theedgemarkets
KUALA LUMPUR (July 4): The FBM KLCI rose at midday break today, lifted by gains at select index-linked blue chips, including Telekom Malaysia Bhd and Axiata Group Bhd, against the backdrop of weaker regional markets.
HLFBF 7084 1082 5031 BATS 4162 1163 0023 KLKBY 2445 4588 4863 5347 3867 0037 0026 TNABY 6888 5819 AXXTF MYTEF TNABF 3719

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...